<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>MicroRNAs (miRs) are short non-coding <z:chebi fb="40" ids="33697">RNAs</z:chebi> that bind complementary sequences in <z:chebi fb="2" ids="33699">mRNA</z:chebi> resulting in translation repression and/or <z:chebi fb="2" ids="33699">mRNA</z:chebi> degradation </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated expression of the reported <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>-associated miRs-335, 206, 135a, 146a, 146b, 10b, 21, let7a and let7b in <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa, non-metastatic and <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Expression of target miRs in micro-dissected paraffin embedded tissues was evaluated in 15 primary <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> with adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> tissue from patients that were disease-free at 4Â years (cohort A) and 19 paired <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumours</z:e> with corresponding <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> (cohort B) by quantitative real-time PCR </plain></SENT>
<SENT sid="3" pm="."><plain>Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, while miR-206 demonstrated an opposite trend </plain></SENT>
<SENT sid="4" pm="."><plain>The levels of mir-21 did not associate with the expression of PTEN, an important <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> compared to <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa or non-<z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e>, and only in KRAS mutation positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> had a specificity of 87% and sensitivity of 76% for the presence of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In summary, we have shown stage-associated differential expression of five out of nine tested <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>-associated miRs </plain></SENT>
<SENT sid="8" pm="."><plain>We have further found that an analysis of these five miRs expression levels in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> significantly correlates with the presence of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e>, making this a potential clinically useful prognostic tool </plain></SENT>
</text></document>